ANG Lifesciences India Ltd

ANG Lifesciences India Other Announcement

ANG Lifesciences India Ltd has filed its quarterly shareholding pattern as required under SEBI Regulation 31(1)(b).

ANG Lifesciences India Annual Report

ANG Lifesciences India Limited has submitted its Annual Report for the financial year 2025-26, including the notice convening its 20th Annual General Meeting.

ANG Lifesciences India Annual General Meeting

ANG Lifesciences India Limited has scheduled its 20th Annual General Meeting for September 30, 2026, to be conducted via Video Conference.

ANG Lifesciences India Board Meeting Outcome

ANG Lifesciences announced the outcome of its board meeting, approving the Board's report, appointing a cost auditor, and scheduling the 20th AGM for September 30, 2026.

ANG Lifesciences India Q1 FY27 Results: Net Loss of ₹4.2 Cr, Loss Widens

ANG Lifesciences India Ltd reported revenue from operations of ₹15.3 Cr (-37.8% YoY) and a net loss of ₹4.2 Cr for Q1 FY27.

Key figure

Net loss ₹4.2 Cr

ANG Lifesciences India Board Meeting Date

ANG Lifesciences India Ltd has scheduled a board meeting on August 14, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.

ANG Lifesciences India Q4 FY26 Results: Net Loss of ₹1.4 Cr, Loss Narrows

ANG Lifesciences India Ltd reported revenue from operations of ₹23.5 Cr (+39.9% YoY) and a net loss of ₹1.4 Cr for Q4 FY26.

Key figure

Net loss ₹1.4 Cr

ANG Lifesciences India Financial Results

ANG Lifesciences approved audited standalone and consolidated financial results for FY2026. The board meeting concluded with an unmodified audit opinion from statutory auditors.

ANG Lifesciences India Other Announcement

ANG Lifesciences India Limited submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The report confirms overall regulatory adherence while highlighting minor administrative delays.

ANG Lifesciences India Board Meeting Date

ANG Lifesciences scheduled a board meeting on May 30, 2026, to approve audited financial results. The trading window remains closed until June 1, 2026.

ANG Lifesciences India Debt & Borrowing

ANG Lifesciences India Ltd has disclosed that it does not fall under the 'Large Corporate' category for the financial year 2025-26 as per SEBI norms. Consequently, requirements for incremental borrowing via debt securities and annual disclosures are not applicable. The company reported zero outstanding borrowings as of March 31.

ANG Lifesciences India Price Movement Clarification

ANG Lifesciences India Ltd clarified to BSE that recent share price movements are purely market-driven. The company confirmed there is no undisclosed price-sensitive information or pending announcements that could impact trading volume or price behavior.

ANG Lifesciences India Q3 FY26 Results: Net Loss of ₹4.7 Cr, Loss Narrows

ANG Lifesciences India Ltd reported a net loss of ₹4.7 Cr for Q3 FY26.

Key figure

Net loss ₹4.7 Cr